SCHEMBL21865717

SCHEMBL21865717

CC1CCC(OCCOc2ccc(-c3cc(=O)c4cccc(Cl)c4o3)cc2)C1

nearest known ligand 0.44

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ ABCB1 P08183 3/20 0.44
▸ MAOB P27338 1/20 0.43
▸ BCHE P06276 2/20 0.41
▸ CNR2 P34972 1/20 0.41
▸ SIGMAR1 Q99720 2/20 0.41
▸ ACHE P22303 1/20 0.41
▸ ABCG2 Q9UNQ0 4/20 0.40
▸ ABCC1 P33527 2/20 0.40
▸ HRH3 Q9Y5N1 1/20 0.40
▸ CYP1A1 P04798 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP1B1 Q16678 1/20 0.39
▸ CYSLTR1 Q9Y271 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21801131 0.87 CYSLTR1 (0.43) ABCB1MAOBBCHECNR2SIGMAR1
SCHEMBL21865634 0.87 ABCB1 (0.43) ABCB1MAOBBCHECNR2SIGMAR1
SCHEMBL21801232 0.87 MAOB (0.44) ABCB1MAOBBCHECNR2SIGMAR1
SCHEMBL21886504 0.86 ABCB1 (0.44) ABCB1MAOBBCHECNR2SIGMAR1
SCHEMBL21886451 0.86 ABCB1 (0.42) ABCB1MAOBBCHECNR2SIGMAR1
SCHEMBL21801063 0.85 CYSLTR1 (0.45) ABCB1MAOBBCHECNR2SIGMAR1
SCHEMBL21801062 0.85 CYSLTR1 (0.45) ABCB1MAOBBCHECNR2SIGMAR1
SCHEMBL21801118 0.85 CYSLTR1 (0.45) ABCB1MAOBBCHECNR2SIGMAR1
SCHEMBL21801221 0.85 SIGMAR1 (0.47) ABCB1MAOBBCHECNR2SIGMAR1
SCHEMBL30744108 0.85 SIGMAR1 (0.47) ABCB1MAOBBCHECNR2SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3849966-B1 FLAVONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE HOFFMANN LA ROCHE (CH) 2023-10-25 — — EP disclosed
WO-2020053249-A1 FLAVONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2020-03-19 — — WO disclosed
Send feedback